Horizon Healthcare Services offers patients and their families the special coordinated care they need in the comfort and security of the home environment.  - Range of flexible, customized treatment therapies, from single therapies such as IV antibiotic therapy, to highly complex therapies - 24-hour intake and free insurance verification prior to service - Consistently high patient satisfaction - Experienced pharmacists - Accreditation by the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO)

Horizon Healthcare Services

Med-Metrix provides Performance Management and Revenue Cycle solutions to the healthcare industry. Designed specifically to improve clients' margins and productivity, their offerings leverage their proprietary FLOWtechnology platform Â® of graphic-rich reporting and automated workflow coupled with advisory and outsource services as needed.

Med-Metrix

Horizon Blue Cross Blue Shield of New Jersey, the only licensed Blue Cross and Blue Shield plan in New Jersey, provides health insurance coverage to more than 3.8 million people throughout all of North, Central, and South Jersey. Horizon Blue Cross Blue Shield of New Jersey is best known for our managed care and traditional indemnity plans for individuals and employers — the cornerstone of our health care business. Horizon BCBSNJ traces its history back to 1932 when Associated Hospitals of Essex County, Inc. was formed as a multi-hospital prepayment plan. The company later became the nation's first Blue Cross Plan.

Horizon Blue Cross Blue Shield of New Jersey

Boston Millennia Partners (BMP) has a long and successful history of growth capital investing on a national scope. Our Core Company Investment Strategy, combined with our international network of relationships and deep industry expertise, sets us apart from other investor groups and enables us to contribute meaningfully to our portfolio companies. The company focuses on investment opportunities within the healthcare and business services industries. Outsourcing and software as a service business companies are of particular interest for investment. Boston Millennia Partners' goal is to be supportive and effective investing partners, and establish productive relationships with its business partners that create long-term value. The company seeks to partner with entrepreneurs who share our goal of building enduring, large-scale businesses that result in personal fulfillment and superior financial returns.  Over the past thirty years, it has implemented an investment approach that centers on active participation with our portfolio companies.  Its goal is to be supportive and effective investing partners and establish productive relationships with its business partners that create long-term value.

Boston Millennia Partners

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.  Their mission is to discover new ways to improve and extend people's lives.  They apply their expertise in science and innovation to society’s biggest health challenges. Responsibility is a core part of their business strategy.

Novartis

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene

Foundation Medicine plans to create clinical diagnostic tests that can use the latest in genetic sequencing technology to identify personalized cancer therapies for patients.

Foundation Medicine

Founded in 2015, dRx Capital is Novartis' Digital Health Venture Fund investing in entrepreneurs transforming healthcare through data and digital technology. The fund invests in technology platforms improving access to healthcare and reimagining the practice of medicine, with a focus on AI & ML, big data, R&D optimization, patient care, and pharma supply chain and commercialization.

dRx Capital

Regional Cancer Care Associates (RCCA) is one of the largest oncology oncology physician networks in the United States

Regional Cancer Care Associates

Baptist Health South Florida is a health care organization, operates medical plazas, surgical facilities, and hospitals.

Baptist Health South Florida

ONC Capital is a growth and expansion firm that actively seeks new investments.  In 2020 the firm has funded COTA, provider of proprietary technology and advanced analytics in the healthcare industry.

ONC Capital

Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world's largest and most established healthcare venture capital firms. The team is comprised of 23 professionals with principal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience.  For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.

Essex Woodlands Healthcare Partners

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

Deerfield

IQVIA  is a provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. The company generates and analyzes information on a scale that aids healthcare stakeholders in identifying disease patterns and correlating with the precise treatment path and therapy required for better outcomes. It does this by using a wide range of privacy-enhancing technologies and safeguards to protect individual privacy.

IQVIA

Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, they are one of 41 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment.  The close collaboration between their physicians and scientists is one of their unique strengths, enabling us to provide patients with the best care available as they work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Their education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan Kettering has an impact on cancer treatment and biomedical research around the world.

Memorial Sloan - Kettering Cancer Center

Hackensack Meridian Health is a not-for-profit health care organization that offers medical services, research, and life care. They manage ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, and urgent care centers.

Hackensack Meridian Health

Atoc Holdings

COTA Healthcare

COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.

<div>COTA Healthcare is a bioinformatics startup that provides real-world data and analytics solutions focused on cancer care. COTA&rsquo;s platform uses data from a wide range of data sources, including electronic health records, clinical trials, and patient registries. Through its proprietary technology and analytics, COTA organizes and analyzes this data to offer insights into patient outcomes, treatment effectiveness, and the cost-effectiveness of various treatments. These insights have the potential to enhance patient care, expedite drug development, and guide policy decisions.</div>

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Google Cloud

COTA, Inc., an oncology real-world data and analytics company, enters into a new partnership with Google Cloud to develop algorithms that will extract and make sense of unstructured data from electronic health records (EHRs).

Enabling the health systems to seamlessly connect, exchange, and interpret shared data

Hospital Interoperability

Includes tools that allow healthcare providers to aggregate clinical data (both structured and unstructured) from a variety of sources and share this information with other providers, patients, or insurance providers.

<div>
 
 COTA Healthcare is a bioinformatics startup that provides real-world data and analytics solutions focused on cancer care. COTA&rsquo;s platform uses data from a wide range of data sources, including electronic health records, clinical trials, and patient registries. Through its proprietary technology and analytics, COTA organizes and analyzes this data to offer insights into patient outcomes, treatment effectiveness, and the cost-effectiveness of various treatments. These insights have the potential to enhance patient care, expedite drug development, and guide policy decisions.
 
 
 
 
 The firm offers six different services to cater to the diverse needs of its target audience. These offerings encompass real-world data analytics, data abstraction and curation, as well as data consulting and advisory services. Operating as a B2B entity, COTA collaborates with pharmaceutical companies, academic institutions, healthcare providers, and health plans. As of May 2023, the company had over 2 million individuals diagnosed with cancer and more than 1,500 providers in its network.&nbsp;
 
 
 Key customers and partnerships
 
 
 In March 2021, the company partnered with Kite, a Gilead company, through which COTA&rsquo;s real-world data would be used to accelerate Kite&rsquo;s drug development pipeline. The company partnered with molecular testing company Genomic Testing Cooperative (GTC) in March 2023&nbsp; to combine COTA&rsquo;s clinical oncology real-world data with GTC&rsquo;s genomics testing data to support precision medicine-based care delivery. The company has also partnered with leading cancer organizations, including the American Cancer Society, the National Cancer Institute, and the Dana-Farber Cancer Institute.
 
 
 Funding and financials
 
 
 The company&rsquo;s most recent funding round was in October 2022, where it raised an unspecified amount in a Series E funding round led by Deerfield Management. The funds were used to accelerate and further diversify COTA's oncology real-world data products and services. 
 
 
 
</div>

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>
 
 COTA Healthcare is partnering with Precision Health Informatics, a branch of Texas Oncology. The aim is to improve precision medicine in community cancer centers by using COTA's AI technology, CAILIN, to analyze complex healthcare data.
 Through the processing of electronic health records (EHRs) and the use of quality real-world data (RWD), the collaboration hopes to offer personalized, precision medicine to cancer patients.
 
</div>

COTA Healthcare

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless